NATCO Pharma Limited (BOM:524816)

NATCO Pharma Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	-	15,509	1,200	704	1,319	1,111
Short-Term Investments	-	5,782	23,699	13,208	6,612	6,488
Cash & Short-Term Investments	21,291	21,291	24,899	13,912	7,931	7,599
Cash Growth	-14.73%	-14.49%	78.97%	75.41%	4.37%	-7.07%
Accounts Receivable	-	8,812	12,466	11,889	8,561	6,206
Other Receivables	-	-	1,045	706	351	545
Receivables	-	8,910	13,605	12,685	9,014	6,855
Inventory	-	9,085	8,494	7,917	8,089	8,620
Prepaid Expenses	-	-	305	289	283	326
Other Current Assets	-	11,237	5,397	5,432	4,686	1,467
Total Current Assets	-	50,523	52,700	40,235	30,003	24,867
Property, Plant & Equipment	-	28,391	26,573	24,350	23,034	23,084
Long-Term Investments	-	25,489	1,528	959	873	1,044
Goodwill	-	630	574	560	552	507
Other Intangible Assets	-	1,943	2,087	1,371	1,326	822
Long-Term Deferred Tax Assets	-	2,326	501	194	-	-
Other Long-Term Assets	-	1,435	2,345	1,394	786	767
Total Assets	-	110,737	86,308	69,063	56,574	51,091

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	-	4,093	2,749	2,355	2,638	1,618
Accrued Expenses	-	-	977	843	691	569
Short-Term Debt	-	6,064	2,731	3,781	1,744	4,205
Current Portion of Leases	-	33	17	27	6	35
Current Income Taxes Payable	-	5	790	323	101	9
Other Current Liabilities	-	6,614	2,171	2,399	1,651	668
Total Current Liabilities	-	16,809	9,435	9,728	6,831	7,104
Long-Term Debt	-	1,000	-	-	-	-
Long-Term Leases	-	42	46	53	11	80
Pension & Post-Retirement Benefits	-	-	181	266	468	574
Long-Term Deferred Tax Liabilities	-	2	2	2	124	301
Other Long-Term Liabilities	-	673	521	483	402	396
Total Liabilities	-	18,526	10,185	10,532	7,836	8,455

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	-	358	358	358	365	365
Additional Paid-In Capital	-	-	12,019	12,019	14,065	14,078
Retained Earnings	-	-	63,061	45,252	33,518	27,261
Comprehensive Income & Other	-	91,853	632	902	790	932
Total Common Equity	92,211	92,211	76,070	58,531	48,738	42,636
Minority Interest	-	-	53	-	-	-
Shareholders' Equity	92,211	92,211	76,123	58,531	48,738	42,636
Total Liabilities & Equity	-	110,737	86,308	69,063	56,574	51,091

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	7,139	7,139	2,794	3,861	1,761	4,320
Net Cash (Debt)	14,152	14,152	22,105	10,051	6,170	3,279
Net Cash Growth	-36.18%	-35.98%	119.93%	62.90%	88.17%	-38.57%
Net Cash Per Share	79.02	79.02	123.42	56.00	33.80	17.98
Filing Date Shares Outstanding	179.1	179.08	179.11	179.11	182.47	182.52
Total Common Shares Outstanding	179.1	179.08	179.11	179.11	182.47	182.52
Working Capital	-	33,714	43,265	30,507	23,172	17,763
Book Value Per Share	514.92	514.92	424.71	326.79	267.10	233.60
Tangible Book Value	89,638	89,638	73,409	56,600	46,860	41,307
Tangible Book Value Per Share	500.55	500.55	409.85	316.01	256.81	226.31
Land	-	-	5,265	3,692	2,855	2,641
Buildings	-	-	11,090	11,080	10,593	9,734
Machinery	-	-	19,485	18,340	17,616	16,798
Construction In Progress	-	-	2,254	1,373	643	1,295

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 20, 2026

Data Sources Report a data error